|Systematic (IUPAC) name|
|Half-life||38.0 to 59.1 hours|
|(what is this?)|
Nilutamide is an antiandrogen medication used in the treatment of advanced-stage prostate cancer. Nilutamide blocks the androgen receptor, preventing its interaction with testosterone. Because most prostate cancer cells rely on the stimulation of the androgen receptor for growth and survival, nilutamide can prolong life in men with prostate cancer. Nilutamide is marketed under the name Nilandron in the United States and under the name Anandron in Canada.
- Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J. Urol. 2003 May;169(5):1742-4. PMID 12686822
- Moguilewsky M, Bertagna C, Hucher M. (1987) Pharmacological and clinical studies of the antiandrogen Anandron (nilutamide). J Steroid Biochem. (4-6):871-5.
- Hsieh AC, Ryan CJ. (2008) Novel concepts in androgen receptor blockade. Cancer J. 14(1):11-14.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|
|This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.|